Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

AAA_UGE - pending
Research Report

Share on Stocktwits


text

 

Disclosures for iA Capital Markets, UGE, Jan. 12, 2022

The research analyst and or associates who prepared this report are compensated based upon the overall profitability of iA Capital Markets, which may include the profitability of investment banking and related services. iA Capital Markets may buy from or sell to customers the securities of issuers mentioned in this report on a principal basis.

Analyst's Certification: Each iA Capital Markets research analyst whose name appears on the front page of this research report hereby certifies that (i) the recommendations and opinions expressed in this research report accurately reflect  the research analyst's personal views about the issuer and securities that are the subject of this report and all other companies and securities mentioned in this report that are covered by such research analyst and (ii) no part of the research analyst's compensation was, is, or will be directly or indirectly, related to the specific recommendations or views expressed by such research analyst in this report.

As a condition of employment, analysts are required to adhere to the Code of Ethics and Standards of Professional Contact of the CFA Institute.

iA Capital Markets permits analysts to own and trade in the securities and or the derivatives of the issuer under their research coverage subject to the following restrictions. No trades can be executed in anticipation of coverage for a period of 30 days prior to the issuance of the report and 5 days after the dissemination of the report to our clients. For a change in recommendation, no trading is allowed for a period of 24 hours after the dissemination of such info to our clients. A transaction against an analyst's rec can only be executed for a reason unrelated to the outlook of the stock for the issuer and with the prior approval of the Director of Research and the Chief Compliance Officer.

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe